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Abstract
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Objectives—Polymerase chain reaction (PCR) has been shown to have an excellent sensitivity
and specificity for the detection of Clostridium difficile infection (CDI). Little is known about risk
factors for CDI within 14 days of an initial negative test. We sought to determine the
characteristics among hospitalized patients associated with risk of short-term acquisition of CDI.
Methods—A case-control study was conducted. Cases were patients who converted from PCR
negative to positive within 14 days. Each case was matched with three controls. Conditional
logistic regression was used to estimate the association between patient characteristics and CDI.
Results—Of the 30 patients in our study who had a positive PCR within 14 days of a first
negative PCR (cases), 15 (50%) occurred within 7 days of the initial test. Cases had a higher
proportion of intravenous vancomycin use in the previous 8 weeks (odds ratio [OR], 3.38; 95%
confidence interval [CI], 1.34-8.49) and were less likely to have recent antiviral agent use (OR,
0.30; 95% CI, 0.11-0.83) compared with controls.
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Conclusions—In hospitalized patients, treatment with intravenous vancomycin within the prior
8 weeks of a first negative PCR test for C difficile is a risk factor for short-term risk for hospitalacquired CDI. Repeat testing guidelines for C difficile PCR should take into consideration patients
who may be at high risk for short-term acquisition of CDI.
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Clostridium difficile was not identified as the causative bacterial agent for antibiotic-related
diarrhea until the late 1970s1-3 and is now recognized as the leading cause of infectious
nosocomial (hospital-acquired) diarrhea.3,4 The median onset of symptomatic infection after
colonization with toxigenic C difficile spores is typically 2 to 3 days.5 Recently, molecular
testing has been recognized as an important tool for C difficile infection (CDI) diagnosis,
with a sensitivity and specificity of 73% to 100% and 91% to 100%, respectively.6 Due to
the high specificity of the test, most institutions using polymerase chain reaction (PCR) to
diagnose CDI advocate against repeat testing within 7 days of an initial negative test.7
Short-term acquisition of CDI, meaning a positive PCR test on repeat testing after an initial
negative test within 14 days, is rare, but it does occur in 1% to 4% of patients who undergo
repeat testing, and the specific risk factors are unknown.7-12 Patients with short-term
acquisition of CDI are exclusively inpatients since they are most likely to undergo expedited
repeated testing.7,8 Since repeat PCR testing for C difficile is costly, determining which
patients would likely benefit from repeat testing could be used to guide laboratory
policies.13
The overall goal of this study was to determine if identifiable patient characteristics would
improve the efficiency of a short-term repeat testing protocol for detecting C difficile. The
objectives of this study were to determine the rate of short-term acquisition (within 14 days)
of CDI after an initial negative PCR in our institution and to determine patient
characteristics and antibiotic regimens associated with acquisition.

Materials and Methods
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This case-control study was conducted at a university-affiliated health care system in a large
metropolitan area in the Southeast United States. Adult patients (aged ≥18 years) had a feces
sample ordered in any clinical setting (if the clinician had any concern that the patient may
have had CDI based on the presence of fever, leukocytosis, abdominal pain, diarrhea, or
ileus). All PCR tests sent for testing for C difficile from November 2010 to September 2012
were eligible for the study. From the total pool of PCR tests, those that were repeated within
14 days were identified. Cases were defined as patients with an initially negative PCR test
followed by a subsequent positive PCR test within 14 days of the previous negative test.
Controls were chosen from the same pool of repeat PCR testing but remained negative
during the entire hospital stay Figure 1.
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Cases were matched to three randomly selected controls by (1) days of hospitalization to
first C difficile PCR test (±1 day) and (2) age (range ±10 years). Two of the cases needed to
be paired with two controls outside the age range (±15 years). These variables were selected
for matching because they are established confounders for risk of CDI.14,15
All cases had diarrheal disease indicative of CDI confirmed by chart review and were not
considered colonized by C difficile. Retrospective chart reviews were performed to obtain
patient information on baseline demographics, clinical characteristics, and comorbidities
from the electronic medical record. We chose the following patient characteristics to abstract
based on the literature, including age,14 immunosuppression (chemotherapy16,
neutropenia17, human immunodeficiency virus18), recent gastrointestinal (GI) surgery,19
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tube feeding,20 use of proton pump inhibitors (PPIs),21 and duration of hospitalization.22,23
Antimicrobial use was collected for the following medication classes (both 8 weeks before
and 14 days after first negative test): β-lactam, macrolide, quinolone, aminoglycoside,
trimethoprimsulfamethoxazole, metronidazole, intravenous vancomycin, oral vancomycin,
antifungal, antiviral (acyclovir prophylaxis), linezolid, tetracycline, clindamycin, aztreonam,
daptomycin, and an “other” category. Other clinical variables collected included if the
patient had a GI procedure 8 weeks prior to the first negative test, PPI therapy use within 7
days prior to the first negative test, chronic steroid use (≥10 mg daily prednisone for ≥3
months), intensive care unit (ICU) admission within 7 days prior to testing and/or 48 hours
after testing, and concurrent coinfections (either GI or systemic).
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Variables that were collected specifically after the first negative test include ICU admission
as listed above, antibiotics during the 14-day time period after the first negative test, and
treatment for CDI. All data were entered into a REDCap electronic database.24
Laboratory Measures
All feces samples sent to the clinical microbiology laboratory for C difficile testing were
processed according to the manufacturer's instructions for the Xpert C difficile test (Cepheid,
Sunnyvale, CA), which detects the presence of the toxin B gene by real-time PCR.25
Statistical Analyses
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Data were analyzed using SAS version 9.3 (SAS Institute, Cary, NC) and OpenEpi 2.3.1
(Open Source Epidemiologic Statistics for Public Health, Atlanta, GA). The underlying rate
for the health care system of short-term acquisition of CDI after a first negative test was
calculated using the number of new CDI cases divided by the person days of hospitalized
patients who were tested for C difficile. This calculation assumed that all other individuals in
the hospital were not tested and did not have CDI. Those at risk included the sum of the
person days of the cases until their positive PCR and the total hospital days of the
individuals who had repeat testing but did not become PCR positive. The χ2 test (for
categorical variables) or Wilcoxon rank-sum test (for continuous variables) was used to
assess the association between patient characteristics and incident CDI. A two-sided P value
less than .05 was considered statistically significant. Conditional logistic regression was
used to estimate the adjusted association (adjusted odds ratios [ORs] and 95% confidence
intervals [CIs]) between covariates and acquisition of C difficile, controlling for the matched
patient characteristics (age and days of hospitalization to first PCR test).
Ethical Review

Author Manuscript

The Emory University Institutional Review Board reviewed the study protocols with
expedited approval for minimal risk.

Results
During the study period, a total of 12,021 C difficile PCR tests were performed, and of
those, 9,312 PCR tests were excluded because those patients received only a single test
(Figure 1). Of the 2,709 tests that remained, 430 PCR tests were further excluded because
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the repeated testing was performed after a first positive test. Of the 2,279 that had a repeat
PCR test after a first negative PCR, 1,500 were within 14 days. From these, we identified 60
PCR tests or 30 cases of patients with short-term CDI acquisition who had an initial negative
PCR followed by a positive PCR within 14 days. Fifteen (50%) of the 30 cases acquired
CDI within 7 days of the first negative PCR, which is within the window that repeat testing
is typically rejected from the laboratory.7 The rate of short-term acquisition of CDI in the
study population was 142 per 100,000 person years (95% CI, 97-200 per 100,000 person
years).

Author Manuscript

The patients’ clinical characteristics are shown in Table 1. In total, 120 patients were
included (30 cases and 90 controls), 52.5% (63/120) were male, median age was 60 (range,
25-88) years, and the median hospital stay was 24 (range, 4-143) days. Sixty-one percent
(73/120) had diarrheal disease during the first PCR test; of the cases, 13 (43.3%) had
diarrhea before the first test, and 20 (66.6%) had diarrhea before the second test. There were
no significant differences between cases and controls in patient characteristics and
comorbidities. Compared with controls, cases were more likely to be male (63.3% vs
48.9%), have had a recent GI procedure (26.7% vs 13.3%), and were less likely to have
leukemia (23.3% vs 35.6%), although these differences were not statistically significant.
Table 2 shows antibiotic use. In the 8 weeks prior to the first negative PCR test, cases were
more likely than controls to be receiving intravenous vancomycin (66.7% vs 38.9%; P = .
009) and less likely to be taking antiviral medication (20.0% vs 44.4%; P = .02). In the 14
days after the first negative PCR test, cases were more likely than the controls to be taking
oral vancomycin (16.7% vs 3.3%; P = .01) or metronidazole (33.3% vs 16.7%; P = .05),
which are the treatments for CDI.23

Author Manuscript

After adjusting for age and days of hospitalization prior to first PCR, no patient
characteristics were strongly associated with cases or controls Table 3. In adjusted analysis,
cases were more likely to have end-stage renal disease (ESRD) (OR, 1.71; 95% CI,
0.60-4.19) and be patients with a recent GI procedure (OR, 2.41; 95% CI, 0.84-6.88), but the
detected differences were not statistically significant.
When comparing antibiotic use before the first performed PCR test (Table 3), the odds of
previous intravenous vancomycin was more common among cases than controls (OR, 3.38;
95% CI, 1.34-8.49), while the use of acyclovir for prophylaxis was more common among
the controls (OR, 0.30; 95% CI, 0.11-0.83). When comparing antibiotic use 14 days after the
first PCR test, the odds of taking metronidazole or oral vancomycin (which are established
treatments for CDI) were more common among cases.
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When combining antibiotic classes Table 4, intravenous vancomycin therapy with a βlactam antibiotic in the 8 weeks prior to the first PCR test showed an increased odds in cases
(OR, 2.72; 95% CI, 1.10-6.72). The same effect was seen when combining intravenous
vancomycin, a β-lactam, and a quinolone (OR, 2.60; 95% CI, 1.05-6.46). No antibiotic
combination 14 days after the first test showed statistical significance.
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Discussion
The rate of short-term acquisition in this study is comparable to the crude incidence rates in
other studies,26 and the percentage of PCR tests (4.2%) that were initially negative and
subsequently positive within 14 days is similar to other studies (2.1%-3.4%).7,8,12
In this case-control study of short-term acquisition of CDI among hospitalized patients, we
found that intravenous vancomycin (within 8 weeks prior to the first PCR-negative test) was
significantly more common among cases than among controls (OR, 3.38; 95% CI,
1.34-8.49), even after adjusting for age and length of hospitalization. In addition, we found
that compared with controls, cases were significantly less likely to have a history of
acyclovir prophylaxis (OR, 0.30; 95% CI, 0.11-0.83).

Author Manuscript

The finding that intravenous vancomycin was associated with short-term acquisition of CDI
could be partially explained by the fact that more cases were highly health care experienced
and also had substantial underlying comorbidities such as immunosuppression and ESRD.
This finding has been described before,15 and one study attributed an adjusted OR of 1.9 for
incident CDI (95% CI, 1.7-2.7) if administered for more than 7 days.27 Intravenous
vancomycin can be used for surgical prophylaxis, but in this study, it was used in patients
with culture-directed infections or as empirical treatment for febrile syndromes in
complicated (immuno-compromised, long-term steroid use, or critically ill) patients (data
not shown). In this patient population, almost half were in the ICU during their
hospitalization.

Author Manuscript

Intravenous vancomycin is not indicated as a therapy for C difficile due to poor GI
penetration (ie, low concentrations found in feces of patients receiving intravenous
vancomycin).28 However, intravenous vancomycin is associated with altered microbiota,
specifically selecting for vancomycin-resistant enterococci.29 While intravenous
vancomycin may not be in the causal pathway of short-term acquisition of C difficile, it is
clearly important.

Author Manuscript

Two recent meta-analyses of antibiotic classes and their risk of incident CDI focused
exclusively on community-associated CDI30,31; our hospitalized patient cohort is different,
with almost no patients receiving antimicrobials (such as clindamycin), which are typically
given on an outpatient basis. Our patients tended to be taking intravenous antibiotics and
were being exposed to the hospital reservoir of C difficile. Given this finding, the
assumption was that the increased odds associated with intravenous vancomycin might have
been a surrogate for poly-antimicrobial use. Previous research demonstrated that antibiotic
perturbation is necessary for dysbiosis that allows C difficile to causes disease.32,33
Therefore, chronic comorbidities that may require frequent antibiotic use (and,
consequently, hospital exposure to C difficile spores) or that result in immune compromise
may place individuals at increased risk for short-term acquisition of CDI. The strong
association with intravenous vancomycin reported in our study may be a surrogate for
individuals who are more chronically ill.34
We think that the estimated protective effect of acyclovir was biased due to a higher
proportion of patients with hematologic malignancy in the control population. Our cohort of
Am J Clin Pathol. Author manuscript; available in PMC 2015 November 02.
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750 individuals from which we drew the cases and controls were hospitalized for lengthy
periods (such as hematopoietic stem cell transplant patients), and we randomly oversampled
a group that used acyclovir for prophylaxis.

Author Manuscript

Our study was subject to limitations. First, systematic error due to residual confounding may
have occurred due to the limited covariates from study patients that were available for
collection during chart review. Second, chart reviews performed could not determine the
exact indications for previous antibiotic use. If the indication for antibiotic use was causally
related to short-term CDI risk and associated with other patient covariates used in this study,
confounding by indication could result in biased estimates.35 However, we do not believe
this to be a major problem because most of the time, antibiotics were used for culturedirected infections or as empirical use in febrile syndromes in complicated patients. Another
limitation is that we were unable to determine if patients had previously had CDI. Our
institution used a different test to diagnose CDI (enzyme immunoassay alone) before
November 2010, so it would be very difficult to compare previous diagnosed cases with our
current highly sensitive molecular method.36 Third, the study's laboratory policy is to
automatically reject feces submitted within 7 days of an initial negative test unless the
practitioner requests a test to be performed again, which means we could have missed some
cases/controls due to the clinician not being concerned enough to request a repeat test.

Author Manuscript

The purpose of this study was to delineate a subgroup of patients who would assist
laboratorians in determining a clinical history that may be associated with a short-term risk
of CDI. Given that short-term acquisition while in the hospital is relatively rare, this group
of patients has not been studied to determine if there is a characteristic associated with CDI.
While the standard practice in the clinical microbiology laboratory is to reject feces samples
that are sent for C difficile PCR within 7 days,7 this interval is not derived from biologic
studies that show that C difficile can be detected within 3 to 7 days of infection.5 Although it
is clear that most patients do not need repeated C difficile testing within 14 days, there are
still individuals who test positive within this time frame, and this is an important diagnosis
to make from an individual's standpoint.3
In conclusion, intravenous vancomycin use within the 8 weeks prior was predictive of shortterm acquisition of C difficile in hospitalized patients. The practical implications for this in
terms of repeated testing may include eliciting this antibiotic history when clinicians request
repeat testing earlier than 7 days in a hospitalized patient.
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Cases and controls selected from the total cohort of polymerase chain reaction (PCR) tests
performed from November 2010 to September 2012. n represents the number of PCR tests
(not patients), and % represents the percentage in comparison to the total cohort of PCR
tests (100% cohort = 12,021 PCR tests).
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Baseline Characteristics of Cases and Controls

a

Characteristic

Cases (n = 30)

Controls (n = 90)

P Value

b
Days to first test, median (IQR)

7.8 (5.8)

7.8 (5.7)

.95

Age, median y (IQR)

58.8 (13.5)

58.6 (13.5)

.98

    Female

11 (36.7)

46 (51.1)

.17

    Male

19 (63.3)

44 (48.9)

Hospital stay, median d (IQR)

27.0 (18.0)

22.5 (18.0)

.39

Death (all causes)

5 (16.7)

9 (10.0)

.33

11 (36.7)

43 (47.8)

.29

7 (23.3)

22 (24.4)

.90

18 (60.0)

47 (52.2)

.46

Proton pump inhibitor

26 (86.7)

76 (84.4)

.77

f
Recent GI procedure

8 (26.7)

12 (13.3)

.09

End-stage renal disease

6 (20.0)

11 (12.2)

.29

Leukemia

7 (23.3)

32 (35.6)

.22

Solid tumor

5 (16.7)

9 (10.0)

.33

10 (33.3)

31 (34.4)

.91

Stem cell transplant

1 (3.3)

1 (1.1)

.41

Solid organ transplant

2 (6.7)

9 (10.0)

.58

Sex

c

Intensive care unit stay
d

Diabetes mellitus

Author Manuscript

e

Coinfection

g

Chemotherapy

GI, gastrointestinal; IQR, interquartile range.
a

Author Manuscript

Values are presented as number (%) unless otherwise indicated.

b

Days of hospitalization prior to first Clostridium difficile polymerase chain reaction (PCR) test.

c

Intensive care unit stay within 7 days before or 48 hours after first PCR test.

d

Defined as HbA1c of more than 6.5%.

e
Infection of any type and any source at the time of PCR testing.
f
GI procedure of any type within 8 weeks prior to first PCR test.
g

Received chemotherapy for malignancy within the past 8 weeks.

Author Manuscript
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Table 2

Author Manuscript

Antibiotics Used 8 Weeks Prior to First PCR Test

a

No. (%)
b

Antibiotic

Cases (n = 30)

Controls (n = 90)

β-Lactam

22 (73.3)

50 (55.6)

.09

Quinolone

14 (46.7)

40 (44.4)

.83

Aminoglycoside

1 (3.3)

6 (6.7)

.50

Metronidazole (PO/IV)

2 (6.7)

9 (10.0)

.58

Vancomycin IV

20 (66.7)

35 (38.9)

.009

Acyclovir prophylaxis

6 (20.0)

40 (44.4)

.02

    β-Lactam

19 (63.3)

62 (68.9)

.58

    Quinolone

12 (40.0)

33 (36.7)

.75

    Aminoglycoside

3 (10.0)

6 (6.7)

.55

    Metronidazole (PO/IV)

10 (33.3)

15 (16.7)

.05

    Vancomycin IV

9 (30.0)

43 (47.8)

.09

    Vancomycin PO

5 (16.7)

3 (3.3)

.01

    Acyclovir prophylaxis

8 (26.7)

37 (41.1)

.16

P Value

Antibiotic use 14 days after first PCR test

Author Manuscript

IV, intravenous; PCR, polymerase chain reaction; PO, oral.
a

Other antibiotics analyzed but not shown (as total number of patients receiving them ≤5) were macrolides, trimethoprim-sulfamethoxazole,
antifungals, linezolid, tetracyclines, clindamycin, aztreonam daptomycin, and “others” (carbapenem, dapsone, meropenem, nitrofurantoin, and
tigecycline). None was statistically significant.
b

Bold signifies statistical significance, two-sided P < .05.

Author Manuscript
Author Manuscript
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Table 3

Author Manuscript

Conditional Logistic Regression Matched Odds Ratios for Patient Characteristics and Antibiotic Use
Associated With Short-Term Acquisition of Clostridium difficile

a

b

Characteristic

OR (95% CI)

Male sex

1.87 (0.76-4.18)

Death (all causes)

1.85 (0.54-6.28)
c

0.59 (0.24-1.45)

Intensive care unit stay
Diabetes mellitus

d

0.94 (0.35-2.47)

e

1.49 (0.58-3.82)

Coinfection

Proton pump inhibitor

1.18 (0.37-3.73)

f

2.41 (0.84-6.88)

Recent GI procedure

Author Manuscript

End-stage renal disease

1.72 (0.60-4.19)

Leukemia

0.49 (0.17-1.38)

Solid tumor

1.85 (0.54-6.28)
g

0.94 (0.37-2.40)

Chemotherapy

Stem cell transplant

3.00 (0.19-47.96)

Solid organ transplant

0.67 (0.14-3.09)

Antibiotic use 8 weeks prior to first PCR test

h

Author Manuscript

    β-Lactam

2.35 (0.91-6.07)

    Quinolone

1.10 (0.47-2.59)

    Aminoglycoside

0.50 (0.06-4.15)

    Metronidazole

0.67 (0.14-3.09)

    Vancomycin IV

3.38 (1.34-8.49)

    Acyclovir prophylaxis

0.30 (0.11-0.83)

h
Antibiotic use 14 days after first PCR test
    β-Lactam

0.81 (0.36-1.81)

    Quinolone

1.18 (0.47-2.98)

    Aminoglycoside

1.50 (0.38-6.00)

    Metronidazole

2.39 (0.95-6.06)

    Vancomycin IV

0.47 (0.19-1.16)

    Vancomycin PO

6.63 (1.27-34.74)

    Acyclovir prophylaxis

0.51 (0.20-1.29)

CI, confidence interval; GI, gastrointestinal; IV, intravenous; OR, odds ratio; PCR, polymerase chain reaction; PO, oral.
a

OR matched on age and days to first PCR test.

Author Manuscript

b

Bold signifies statistical significance.

c

Intensive care unit stay within 7 days before or 48 hours after first PCR test.

d

Defined as HbA1c of more than 6.5%.

e
Infection of any type and any source at the time of PCR testing.
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GI procedure of any type within 8 weeks prior to first PCR test.

g

Received chemotherapy for malignancy within the past 8 weeks.

h

Author Manuscript

Other antibiotics analyzed but not shown were macrolides, trimethoprim-sulfamethoxazole, antifungals, linezolid, tetracyclines, clindamycin,
aztreonam, daptomycin, and “others” (carbapenem, dapsone, meropenem, nitrofurantoin, and tigecycline). None was statistically significant.

Author Manuscript
Author Manuscript
Author Manuscript
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Table 4

Author Manuscript

Matched Odds Ratio for Combined Antibiotic Classes Associated With Short-Term Acquisition of
a

Clostridium difficile

b

Antibiotic

OR (95% CI)

Antibiotic class administered 8 weeks prior to first test
    β-Lactam

2.35 (0.91-6.07)

    Quinolone

1.10 (0.47-2.59)

    Vancomycin IV

3.38 (1.34-8.49)

    β-Lactam + vancomycin IV

2.72 (1.10-6.72)

    β-Lactam + vancomycin IV + quinolone

2.60 (1.05-6.46)

Antibiotic class administered 14 days after first test

Author Manuscript

    β-Lactam

0.81 (0.36-1.81)

    Quinolone

1.18 (0.47-2.98)

    Vancomycin IV

0.47 (0.19-1.16)

    β-Lactam + vancomycin IV

0.49 (0.20-1.22)

    β-Lactam + vancomycin IV + quinolone

0.78 (0.35-1.73)

CI, confidence interval; IV, intravenous; OR, odds ratio.
a

OR matched on age and days to first test.

b

Bold signifies statistical significance.

Author Manuscript
Author Manuscript
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